跳至主要内容
临床试验/NCT06794424
NCT06794424进行中(未招募)不适用

Impact of Ziwig Endotest® on the Decision and Management of Patients With Chronic Disabling Pelvic Pain Strongly Suggestive of Endometriosis and Presenting With a Negative or Uncertain Baseline Imaging Workup

ZIWIG1 个研究点 分布在 1 个国家目标入组 2,503 人开始时间: 2025年3月14日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
ZIWIG
入组人数
2,503
试验地点
1
主要终点
Change in the number of laparoscopies related to the test result in women whose decision to undergo laparoscopy was made in multidiscplinary meeting before the test result was obtained. MCID 20%

研究概览

简要总结

The goal of this study is to evaluate the impact of Ziiwg Endotest on patient management decisions before and after the test. The main questions it aims to answer are:

  • Does the test reduce the intention and number of laparoscopies in women whose decision to undergo laparoscopy was made before the test result was obtained?
  • Does the test change management decisions in women with no prior indication for diagnostic laparoscopy?

Study will compare the patient management decision before and after the test.

The acts and procedures performed as part of this research are :

  • Aa saliva sampling (Ziwig Endotest) at inclusion
  • A mutidisciplinary meeting post test (if applicable)
  • Completion at inclusion and 6 month of a quality-of-life questionnaire (EHP-5)
  • Completion at inclusion and 6 month of a VAS for pain
  • Completion at inclusion and 6 month of a Likert satisfaction scale
  • A test results Announcement consultation
  • A visit at 6 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 43 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female aged 18 to 43
  • Strong clinical suspicion of endometriosis based on the following suggestive symptoms: chronic pelvic pain (> 6 months) that is suggestive and disabling (ENA ≥ 8, absenteeism or resistance to level 1 analgesics) ± deep dyspareunia or painful hematuria/micturition with menstrual rhythm or painful rectal discharge/defecation with menstrual rhythm.
  • Endovaginal ultrasound and MRI (unless contraindicated, in which case only one of the 2 examinations is required*) less than 1 year old and of sufficient quality , in compliance with the endometriosis protocol recommended by the HAS**.
  • Clinical-radiological discrepancy confirmed by the investigating gynecologist and a referent radiologist at the investigating center, in compliance with the protocol's positivity criteria and the French ENDOVALIRM guidelines (for characterizing deep lesions on MRI) and/or the ESUR 2017 guidelines (for ovarian lesions) and/or the SUR-US 2024 guidelines (for ultrasound).
  • Woman has dated and signed the consent form.
  • Speaks and understands French
  • Affiliated with the French healthcare system

排除标准

  • Endometriosis diagnosed according to imaging protocol positivity criteria
  • Differential diagnosis and/or adenomyosis made
  • History of isolated dysmenorrhea well controlled by hormonal contraception and no immediate desire for pregnancy,
  • Absence of pelvic pain strongly suggestive of endometriosis.
  • Isolated fatigue
  • Aetiological work-up incomplete or pending before deciding on initial medical decision (infertility work-up in progress, waiting for specialist opinion (algologist, psychologist, etc.), waiting for important test results),
  • Infertility work-up (current or previous), with no signs suggestive of endometriosis.
  • Search for recurrence of known endometriosis
  • Laparoscopy for gynecological reasons other than suspected endometriosis
  • History of cancer
  • Pregnant or breast-feeding women
  • Current bacterial or viral infection or less than one month old
  • Participation in an interventional study or in the exclusion period of an interventional study

结局指标

主要结局

Change in the number of laparoscopies related to the test result in women whose decision to undergo laparoscopy was made in multidiscplinary meeting before the test result was obtained. MCID 20%

时间窗: After 6 months visits

The criterion is estimated after the test result is known. Each of these criteria is estimated independently at 3 different times: 1. After knowledge of the test result, management decided by the physician who carried out the inclusion consultation or at the PCR. 2. At the end of the consultation, shared decision 3. At 6 months: by the adjudication committee: positive opinion A hierarchical sequential analysis will be carried out independently according to the following scheme: Sequence 1: decisional impact of the test on the management decision, if conclusive compared with MCID (main criterion) → sequence 2: decisional impact of the test on the medical decision shared with the patient, if conclusive compared with MCID → sequence 3: percentage of favorable adjudications, conclusive if higher than MCID (highest level of evidence of clinical utility)

Changes in subject management related to Ziwig Endotest® result) in women with no prior indication for diagnostic laparoscopy. MCID 30%.

时间窗: After 6 months visits

The criterion is estimated after the test result is known. Each of these criteria is estimated independently at 3 different times: 1. After knowledge of the test result, management decided by the physician who carried out the inclusion consultation or at the PCR. 2. At the end of the consultation, shared decision 3. At 6 months: by the adjudication committee: positive opinion A hierarchical sequential analysis will be carried out independently according to the following scheme: Sequence 1: decisional impact of the test on the management decision, if conclusive compared with MCID (main criterion) → sequence 2: decisional impact of the test on the medical decision shared with the patient, if conclusive compared with MCID → sequence 3: percentage of favorable adjudications, conclusive if higher than MCID (highest level of evidence of clinical utility)

次要结局

未报告次要终点

研究者

发起方
ZIWIG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
不适用
The evaluation for usefulness of dienogest to prevent decline of ovarian reserve by cystectomy for endometriomasendometrioma
JPRN-UMIN000018569agoya University Graduate School of Medicine, Department of Obstetrics and Gynecology40
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemia
EUCTR2004-003807-19-ESMerck & Co Inc.600
进行中(未招募)
不适用
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaMedDRA version: 7.0Level: LLTClassification code 10027762
EUCTR2004-003807-19-ATMerck, Sharp & Dohme600
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMedDRA version: 7.0 Level: LLT Classification code 10027762Mixed hyperlipidemia
EUCTR2004-003807-19-GBMerck Sharp & Dohme Ltd600
进行中(未招募)
不适用
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMedDRA version: 7.0Level: LLTClassification code 10027762Mixed hyperlipidemia
EUCTR2004-003807-19-HUMerck & Co., Inc.600